Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Hepatitis C, Chronic; Hepacivirus

Treatments: Behavioral: Patient assistance program; Drug: Ribavirin (SCH 18908); Biological: Peginterferon alfa-2b (SCH 54031)

Study type: Observational

Funder types: Industry

Identifiers

NCT00704522

P04281

Details and patient eligibility

About

Patients receiving a patient assistance program during therapy for Hepatitis C will be enrolled into this study. All patients will receive PegIntron pen and Rebetol according to label and the patient assistance program. This study will be compared to similar studies from other clinics using various patient support programs for the purpose of designing future comparative phase IV studies.

Enrollment: 601 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients with hepatitis C

Exclusion criteria

• According to the products' labeling (refer to Warnings, contraindications, and safety sections).

Trial design

601 participants in 1 patient group

Patients with hepatitis C

Description:

Patients receiving a patient assistance program during therapy for hepatitis C at sites in Austria.

Treatment:

Biological: Peginterferon alfa-2b (SCH 54031)

Drug: Ribavirin (SCH 18908)

Behavioral: Patient assistance program